Dutasteride Interactions: CYP3A4 Drugs, Warfarin, Digoxin
Dutasteride interacts most with strong CYP3A4 inhibitors like ketoconazole, raising its levels 2.5-fold. No clinically significant effect on warfarin or digoxin.
Dutasteride Mechanism of Action: The Complete Pathway from Enzyme Inhibition to Clinical Effect
A physician-level explanation of how dutasteride (Avodart) works, covering dual 5-alpha reductase inhibition, DHT suppression kinetics, tissue-level effects in prostate and scalp, and how its pharmacology compares to finasteride.
Dutasteride Pediatric Dosing (Under 12): What Parents and Clinicians Need to Know About Avodart in Children
Dutasteride (Avodart) has no FDA-approved pediatric indication for children under 12. Learn why no established dose exists, what the safety concerns are, and what clinical evidence says about 5-alpha reductase inhibitors in young patients.
Dutasteride Pharmacogenomics: How Genetic Variability Shapes Avodart Response
A clinical deep-dive into how CYP3A4, SRD5A1, SRD5A2, and androgen receptor gene polymorphisms influence dutasteride metabolism, efficacy, and side-effect risk.
How to Safely Stop Dutasteride (Avodart): A Clinician-Guided Discontinuation Protocol
Dutasteride side effects are mostly sexual: erectile dysfunction (6.0% vs 3.7% placebo), low libido, gynecomastia. Most resolve 1-3 months after stopping.
Is Dutasteride (Avodart) Safe for Adolescents Ages 12 to 17?
Dutasteride (Avodart) is not FDA-approved for adolescents. This article covers DHT's role in puberty, known adult adverse effects, reproductive development risks, mental health concerns, and monitoring protocols for off-label adolescent use.
Switching To or From Dutasteride (Avodart): A Clinical Protocol Guide
Everything clinicians and patients need to know about switching between dutasteride, finasteride, and other 5-alpha-reductase inhibitors, with trial evidence, dosing protocols, and pharmacokinetic rationale.
